Cochrane · systematic review · CD007784

HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis

Tunnicliffe, DJ, Palmer, SC, Cashmore, BA, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library

Kidney and Transplant2 versionsAMSTAR 2: not assessed

SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.

Questions

current version

GRADE rated

No studies

Included studies

No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 14.3%Low 1 · 14.3%Moderate 3 · 42.9%High 2 · 28.6%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Current version only

Statin therapy versus placebo or standard of care for people with chronic kidney disease not requiring dialysis

Population: people with chronic kidney disease not requiring dialysis

CD007784.PUB3 (current) · 7 questions

Outcome	Effect	Evidence	Status / GRADE
Major cardiovascular events (MACE) Statin therapy vs placebo or standard of care	RR 0.72 [0.66, 0.79]	14 studies · 36156 participants	High
Death Statin therapy vs placebo or standard of care	RR 0.83 [0.73, 0.96]	13 studies · 34978 participants	High
Rhabdomyolysis Statin therapy vs placebo or standard of care	RR 3.07 [0.13, 75.37]	2 studies · 2618 participants	Very low Downgraded: imprecision
Myocardial infarction Statin therapy vs placebo or standard of care	RR 0.55 [0.42, 0.73]	10 studies · 9475 participants	Moderate Downgraded: risk of bias, imprecision
Stroke Statin therapy vs placebo or standard of care	RR 0.64 [0.37, 1.08]	7 studies · 9158 participants	Moderate Downgraded: risk of bias, imprecision
Kidney failure Statin therapy vs placebo or standard of care	RR 0.98 [0.91, 1.05]	3 studies · 6704 participants	Moderate Downgraded: risk of bias, imprecision
Hospitalisation due to heart failure Statin therapy vs placebo or standard of care	RR 0.7 [0.37, 1.32]	1 study · 579 participants	Low Downgraded: imprecision

Comparison

Population: adults with chronic kidney disease

CD007784.PUB2 · 3 questions

Outcome	Effect	Evidence	Status / GRADE
Major cardiovascular events	RR 0.72 [0.66, 0.79]	13 studies · 36033 participants	High
All‐cause mortality	RR 0.79 [0.69, 0.91]	10 studies · 28276 participants	High
Cardiovascular mortality	RR 0.77 [0.69, 0.87]	7 studies · 19059 participants	Moderate